EGFR overexpression and/or hyperactivation is frequently observed in human cancers including GBM (Xu et al., 2017) and EGFR alterations are used as a prognostic marker for GBM and contribute to EGFR activation-induced drug resistance in GBM (Oprita et al., 2021). Here, EGFR is linked to glioblastoma.